1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Real-time Estimate Cboe Europe  -  05/16 04:42:29 am EDT
10262.00 GBX   -0.23%
03:56aNetScientific Shares Rise on Successful Completion of AstraZeneca Covid-19 Antibody Test
DJ
02:01aPT027, a novel fixed-dose combination of albuterol and budesonide, used as an as-needed rescue medicine, significantly reduced the risk of a severe exacerbation
AQ
05/15AstraZeneca's Asthma Drug Cuts Risk Of Severe Exacerbations In Late-stage Study
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca Says Imfinzi Combination Shows Unprecedented Liver-Cancer Survival Rate

01/19/2022 | 02:59am EDT

By Anthony O. Goriainoff


AstraZeneca PLC said Wednesday that a combination of its Imfinzi immunotherapy with tremelimumab antibodies showed an unprecedented survival rate in liver-cancer patients.

The London-listed pharmaceutical company said results from its Himalaya Phase III trial showed a single dose of tremelimumab added to Imfinzi showed unprecedented survival in first-line unresectable liver cancer. It said that 31% of patients were alive at three years.

The company said that the combination--known as the STRIDE regimen--also showed no increase in severe liver toxicity and that no bleeding risk was observed.

Separately, AstraZeneca said Imfinzi plus chemotherapy reduced the risk of death by 20% in first-line advanced biliary tract cancer when compared with chemotherapy on its own.

"Positive results from the Topaz-1 Phase III trial showed AstraZeneca's Imfinzi, in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically meaningful improvement in overall survival and progression-free survival versus chemotherapy alone as a 1st-line treatment for patients with advanced biliary tract cancer," the company said.


Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com


(END) Dow Jones Newswires

01-19-22 0259ET

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.10% 10270 Delayed Quote.18.53%
ON SEMICONDUCTOR CORPORATION 6.04% 56.18 Delayed Quote.-17.29%
STRIDE, INC. 1.19% 36.58 Delayed Quote.9.75%
All news about ASTRAZENECA PLC
03:56aNetScientific Shares Rise on Successful Completion of AstraZeneca Covid-19 Antibody Tes..
DJ
02:01aPT027, a novel fixed-dose combination of albuterol and budesonide, used as an as-needed..
AQ
05/15AstraZeneca's Asthma Drug Cuts Risk Of Severe Exacerbations In Late-stage Study
MT
05/15PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed..
BU
05/13AstraZeneca, Baili Launch Clinical Trial Collaboration for Lung Cancer Drug Combination
MT
05/13Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispec..
CI
05/13Human ventricular progenitor cells promote the formation of new heart tissue following ..
AQ
05/13N.Korea gets offers of aid to fight COVID as it lacks vaccines
RE
05/12AstraZeneca Joins Accumulus Synergy as a Sponsor to Accelerate the Delivery of Medicine..
AQ
05/11Sanofi Says Nirsevimab Showed Nearly 80% Efficacy Against Respiratory Syncytial Virus
MT
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 43 675 M - -
Net income 2022 5 307 M - -
Net Debt 2022 22 509 M - -
P/E ratio 2022 36,8x
Yield 2022 2,34%
Capitalization 195 B 195 B -
EV / Sales 2022 4,98x
EV / Sales 2023 4,55x
Nbr of Employees 83 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 125,85 $
Average target price 144,07 $
Spread / Average Target 14,5%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC18.53%195 003
JOHNSON & JOHNSON3.38%465 363
PFIZER, INC.-15.46%280 096
ABBVIE INC.13.37%271 251
ELI LILLY AND COMPANY5.58%262 514
ROCHE HOLDING AG-15.85%258 421